Laura Dormer’s Post

🌟 Despite recent therapeutic breakthroughs, Cancer remains a formidable challenge in modern medicine, with certain types proving almost insurmountable. But one company is out to change that... 💪 Rather than focus on the 99% of patients who die from those most lethal cancers, Cure51 has a new approach. Focus on the 1% of patients who actually survive and defy all odds: the Outliers. 🔬 A paradigm shift in cancer research, Cure51 studies miraculous survivors' biology to uncover new therapeutic targets. Using advanced molecular profiling, they aim to make every cancer patient an Outlier, improving survival rates and quality of life. Meet the speakers: 🎤 Nicolas Wolikow, Founder & CEO of Cure51, will share how their multimodal database of 1,300+ Outliers can revolutionize standard care therapies. 🎤 Thankamma Ajithkumar, Clinical Director Laboratories at Cambridge University Hospitals NHS Foundation Trust. 🎤 Jean-Luc Gonfond, a 12-year exceptional survivor of Pancreatic Cancer (PDAC). 💫 Defy the odds and be a part of the change at HLTH Europe 👉 https://lnkd.in/eAMA7B-t #hltheurope #healthcare #healthcarecomms #digitalhealth #healthtech

I'm not sure how I got this far before highlighting CD8, but here we are. 🌰 CD8 in a nutshell: -Arguably, one of the most important biomarkers in the research, clinical, and translational medicine spaces. -CD8 defines cytotoxic effector cells, subsets of natural killer and regulatory cells, and is a co-receptor for MHC-I molecules. -Cytotoxic T cells expressing this marker are the [most powerful] effectors in the anticancer immune response and are integral to the success of cancer immunotherapies. -Acts as a prognostic marker for numerous diseases/cancers including, but not limited to, sepsis, TNBC, renal cancer, and lung SCC. I could go on, but it's Friday. 🎉 Enjoy the photos! #ihc #antibodies #friday #immunesystem #multiplexing

As a recent article in Nature noted, the future of functional precision medicine might be to try to throw everything at treating a particular cancer. This is why SEngine Precision Medicine was featured in Nature -- because we're doing something similar and it's showing results. Many of our patients have exhausted their options for standard of care therapies, so why not open the medicine cabinet (as one of our patients says)? Why not try other treatments to see if they make a difference? As I mention below, this is also common in genomic precision medicine. Our solution, called the PARIS® Test, was created because patients requested it -- and it's finding new treatment options for many fighting cancer. Here's the link to the Nature article: https://lnkd.in/dfbxwXJ4 #functionalmedicine #functionalprecisionmedicine #cancerresearch #organoids #standardofcare #oncologyresearch

Useful information about an important immunostain! #cancerimmunotherapy #immunology #immunostaining #multiplex

Our last observational multicenter retrospective study on YAP Activation Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer is now available! ➡️ https://lnkd.in/dvQRQwgC #gastriccancer #personalizedmedicine

”In the sample of long-term cancer survivors, exercise consistent with guidelines was associated with substantial all-cause mortality benefit driven by both reductions in cancer and noncancer mortality. The cause-specific impact of exercise differed as a function of cancer site.” #health #chronicdisease #cancer #physicalactivity #exercise #lifestylemedicine #exerciseasmedicine #healthyhabits #healthyeating #preventivemedicine

Olga Solomon, Acting Director, DG SANTE, Medical Products and Innovation, European Commission, will be a Speaker within the Hospitals Dealing with Massive Data of Patient Sequencing session of CONVEHO European Hospital Convention, organized in partnership with Federation of European Academies of Medicine (FEAM). The main topics of the session: Role of hospitals in Next-Generation Sequencing (NGS) and Cancer screening and perspectives on precision medicine. More about the Convention on https://lnkd.in/d9PV3gG2 #EuropeanHospitalConvention #Oncology

🔬 Exciting Breakthrough Alert! Researchers at King George's Medical University (KGMU) are transforming gallbladder cancer diagnosis! By combining two blood markers, Prof Preeti Agrawal and her team have pioneered a method with near-perfect accuracy. Unlike the current approach, which can lead to misdiagnosis due to its association with pancreatic cancer, this innovative technique integrates carbohydrate antigen 242 (CA242) alongside CA 19-9, elevating detection rates to unprecedented levels. Published in the International Journal of Research in Medical Sciences, their findings highlight the potential to revolutionize early detection, reduce misdiagnosis, and ultimately improve patient outcomes. S Stay tuned as KGMU leads the charge in medical innovation! 🌟 #MedicalResearch #CancerDetection #gallbladdercancer #bodyrevival

“The Hartwig Medical Database makes translational research in lung cancer much more logical and not anymore “trial-and-error": Harry Groen, chest physician UMCG Would you like to use this data, too? https://lnkd.in/excwE-kp.  The data is anonymized and made available free of charge to cancer research institutes and hospitals. It is used by research groups all over the world. Hartwig Medical Foundation is a not-for-profit organization that promotes scientific research in the fight against and treatment of cancer and other diseases, in the broadest sense and provided it is in the public interest.   #cancerresearch #cancergenomics #bioinformatics #lungcancer

Astatine is considered one of the rarest natural elements on earth and exhibits 32 isotopes, none of which are stable. Most of these isotopes are α-emitters, but only At-211 exhibits physical properties suitable for use in therapy. Scientists from the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) have released the first results of clinical trials with 211At-BC8-B10 in more than 40 patients with different types of leukemia. They suggest that At-211 could deliver enough radiation to target diseased white blood cells, minimizing exposure to the rest of the body and healthcare personnel. To know more: Clinical Trial: https://buff.ly/3KERFir Oncidium education: https://buff.ly/3KJbIfB #leukemia #lymphoma #nuclearmedicine #theranostics #cancerresearch #cancerawareness